ESTRO meets Asia 2024 - Abstract Book
S237
Interdisciplinary – Other
ESTRO meets Asia 2024
17. Kawahara D, Saito A, Nagata Y. Improved biological dosimetric margin model for different PTV margins with stereotactic body radiation therapy in homogeneous and nonhomogeneous tumor regions. Reports Pract Oncol Radiother. 2022 Oct 31;27(5):768–77. 18. Wulf J, Haedinger U, Oppitz U, Thiele W, Mueller G, Flentje M. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: A noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol. 2004 Sep;60(1):186–96.
19. Park JM, Kim J, Wu H-G. Technological Advances in Charged-Particle Therapy. Cancer Res Treat. 2021 Jul 15;53(3):635–40.
20. Zheng X-K, Chen L-H, Yan X, Wang H-M. Impact of prolonged fraction dose-delivery time modeling intensity modulated radiation therapy on hepatocellular carcinoma cell killing. World J Gastroenterol WJG. 2005;11(10):1452.
21. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol. 2000;35(2):71–103.
22. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955;9(4):539.
23. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer. 2008 Dec;8(12):967–75.
24. Yap ML, Zubizarreta E, Bray F, Ferlay J, Barton M. Global Access to Radiotherapy Services: Have We Made Progress During the Past Decade? J Glob Oncol. 2016 Aug;2(4):207–15.
25. Laskar SG, Sinha S, Krishnatry R, Grau C, Mehta M, Agarwal JP. Access to Radiation Therapy: From Local to Global and Equality to Equity. JCO Glob Oncol. 2022;8:e2100358.
26. Check DK, Chawla N, Kwan ML, Pinheiro L, Roh JM, Ergas IJ, et al. Understanding racial/ethnic differences in breast cancer-related physical well-being: the role of patient–provider interactions. Breast Cancer Res Treat. 2018 Aug 5;170(3):593–603.
435
Proffered Paper
Four-years audit of radiation treatment time and compliance to radiotherapy in Head-Neck Cancer
Adrija Ghosh 1 , Yousra Izzuddeen 1 , Tenzin Choden 1 , Abhilash Dagar 1 , Supriya Mallick 1 , Alok Thakar 2 , DN Sharma 1 , Aman Sharma 1
1 Radiation Oncology, NCI-AIIMS, Delhi, India. 2 Head Neck Surgery, NCI-AIIMS, Delhi, India
Purpose/Objective:
Prolongation of radical treatment Head Neck Carcinoma (HNC) has been associated with poor treatment outcomes.1,2 A previous audit of compliance (where majority of patients were treated with 2D radiotherapy) from the department showed that 14% of HNC patients could not complete treatment and only 19% completed radical
Made with FlippingBook flipbook maker